Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 84

Results For "ED"

8078 News Found

Aster DM Healthcare launches a 506-bed multi-specialty hospital in Bengaluru
Healthcare | November 02, 2023

Aster DM Healthcare launches a 506-bed multi-specialty hospital in Bengaluru

Aster Whitefield will be Aster's 3 rd multi-specialty hospital in Bengaluru and overall 19th hospital in India


Mankind Pharma Q2 FY24 consolidated PAT higher at Rs. 501.02 Cr
News | November 01, 2023

Mankind Pharma Q2 FY24 consolidated PAT higher at Rs. 501.02 Cr

Mankind Pharma has reported total income of Rs. 2768.07 crores during the period ended September 30, 2023


Thyrocare Technologies posts Q2 FY24 consolidated PAT at Rs. 20.34 Cr
News | November 01, 2023

Thyrocare Technologies posts Q2 FY24 consolidated PAT at Rs. 20.34 Cr

Thyrocare Technologies has reported total income of Rs. 150.17 crores during the period ended September 30, 2023


Ajanta Pharma posts Q2 FY24 consolidated PAT at Rs. 195.30 Cr
News | November 01, 2023

Ajanta Pharma posts Q2 FY24 consolidated PAT at Rs. 195.30 Cr

Ajanta Pharma has reported total income of Rs. 1049.77 crores during the period ended September 30, 2023


EnginZyme produces key mRNA vaccine ingredient using biocatalysis
Biotech | October 30, 2023

EnginZyme produces key mRNA vaccine ingredient using biocatalysis

2023 Nobel laureates discovered how pseudouridine could make mRNA suitable for vaccines


Dr Reddy's Q2 FY24 PAT jumps 33% to Rs 1,480 Cr
News | October 30, 2023

Dr Reddy's Q2 FY24 PAT jumps 33% to Rs 1,480 Cr

Dr Reddy’s Laboratories recorded revenue of Rs 6,880.20 crore during the quarter


Pfizer and BioNTech announce data for mRNA-based vaccine program for influenza and COVID-19
News | October 30, 2023

Pfizer and BioNTech announce data for mRNA-based vaccine program for influenza and COVID-19

The companies plan to start a pivotal Phase 3 trial in the coming months


Enhertu approved in the EU as the first HER2-directed therapy for patients with HER2-mutant advanced non-small cell lung cancer
Drug Approval | October 26, 2023

Enhertu approved in the EU as the first HER2-directed therapy for patients with HER2-mutant advanced non-small cell lung cancer

Approval based on DESTINY-Lung02 results where AstraZeneca and Daiichi Sankyo’s Enhertu demonstrated a confirmed objective response rate of 49% and median duration of response of 16.8 months in previously treated patients


Venus Remedies earns REO Certification from CII for second consecutive year
News | October 26, 2023

Venus Remedies earns REO Certification from CII for second consecutive year

The Responsible Export Organisation (REO) certification is a distinguished recognition awarded by the Confederation of Indian Industry (CII)


Indoco Remedies posts consolidated Q2FY24 PAT at Rs. 35.08 Cr
News | October 23, 2023

Indoco Remedies posts consolidated Q2FY24 PAT at Rs. 35.08 Cr

The company has reported total income of Rs. 486.16 crores during the period ended September 30, 2023